Current therapeutics against HCV

Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol. 2015;28(1):55–65.

Altmann SW, et al. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochim Biophys Acta Mol Cell Biol Lipids. 2002;1580(1):77–93. https://doi.org/10.1016/S1388-1981(01)00190-1.

Bachmetov L, et al. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat. 2012. https://doi.org/10.1111/j.1365-2893.2011.01507.x.

Bartenschlager R. Hepatitis C virus: from molecular virology to antiviral therapy. 1st ed, vol. 369. Heidelberg: Springer; 2013.

Black S, et al. P0891: resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: the C-worthy study. J Hepatol. 2015;62(1):S677–8. https://doi.org/10.1016/s0168-8278(15)31094-1.

Bonaventura A, Montecucco F. Sofosbuvir/velpatasvir: a promising combination. World J Hepatol. 2016;8(19):785–9. https://doi.org/10.4254/wjh.v8.i19.785.

Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, McLauchlan J. Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic. 2008;9(8):1268–82. https://doi.org/10.1111/j.1600-0854.2008.00767.x.

Bourlière M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–46. https://doi.org/10.1056/NEJMoa1613512.

Butler MS, Robertson AAB, Cooper MA. Natural product and natural product derived drugs in clinical trials. Nat Prod Rep. 2014. https://doi.org/10.1039/c4np00064a.

Caillet-Saguy C, Simister PC, Bressanelli S. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. J Mol Biol. 2011;414(3):370–84. https://doi.org/10.1016/j.jmb.2011.10.001.

Chiereghin N, MacManus D, Savill M, Dupuis R. Dynamic distortion simulations for curved aeronautical intakes. Adv Aero Concepts Des Oper. 2014;21:1393–403. https://doi.org/10.1128/MCB.21.4.1393.

Diana G, Gregory H. Ledipasvir/sofosbuvir (Harvoni): Improving options for hepatitis C virus infection. Pharm Ther. 2015;40(4):256–76.

Douglas MW, Tay ES, Eden J-S, George J. Hepatitis C virus genotype 8 infection—successful treatment with sofosbuvir/velpatasvir. J Infect Dis. 2019;220(4):720–2. https://doi.org/10.1093/infdis/jiz155.

Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol. 2014;61(1):S3–13. https://doi.org/10.1016/j.jhep.2014.06.031.

Durantel D. Celgosivir, an α-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs. 2009;10(8):860–70.

Fofana I, Jilg N, Chung RT, Baumert TF. Entry inhibitors and future treatment of hepatitis C. Antivir Res. 2014;104(1):136–42. https://doi.org/10.1016/j.antiviral.2014.02.001.

Gastaminza P, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol. 2006;80(22):11074–81. https://doi.org/10.1128/jvi.01150-06.

German P, Mathias A, Brainard D, Kearney BP. Clinical pharmacokinetics and pharmacodynamics of ledipasvir/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C. Clin Pharmacokinet. 2016;55(11):1337–51. https://doi.org/10.1007/s40262-016-0397-0.

Havinga RM, Hartl A, Putscher J, Prehsler S, Buchmann C, Vogl CR. Tamarindus indica L. (Fabaceae): patterns of use in traditional African medicine. J Ethnopharmacol. 2010. https://doi.org/10.1016/j.jep.2009.11.028/.

Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013;13(7):535–42. https://doi.org/10.1038/nri3463.

Horner SM, Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med. 2013;19(7):879–88. https://doi.org/10.1038/nm.3253.

Ikeda M, Abe KI, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44(1):117–25. https://doi.org/10.1002/hep.21232.

Jacobson IM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16. https://doi.org/10.1056/NEJMoa1012912.

Jacobson IM, et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology. 2012;56(2):567–75. https://doi.org/10.1002/hep.25865.

Jiang L, et al. Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein. Biotechnol Lett. 2012;34(12):2205–12. https://doi.org/10.1007/s10529-012-1034-0.

Jopling CL, Yi MK, Lancaster AM, Lemon SM, Sarnow P. Molecular biology: modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (80-). 2005;309(5740):1577–81. https://doi.org/10.1126/science.1113329.

Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015;9(2):161–73. https://doi.org/10.1007/s12072-014-9606-9.

Lau DTY, Fish PM, Sinha M, Owen DM, Lemon SM, Gale M. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology. 2008;47(3):799–809. https://doi.org/10.1002/hep.22076.

Lindow M, Kauppinen S. Discovering the first microrna-targeted drug. J Cell Biol. 2012;199(3):407–12. https://doi.org/10.1083/jcb.201208082.

Link JO, et al. Discovery of velpatasvir (GS-5816): a potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa. Bioorg Med Chem Lett. 2019;29(16):2415–27.

“Mavyret,” no. Md, 2018; pp 1–7.

Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350–9. https://doi.org/10.1136/gut.2005.076646.

Meuleman P, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology. 2008;48(6):1761–8. https://doi.org/10.1002/hep.22547.

Meuleman P, et al. A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology. 2012;55(2):364–72. https://doi.org/10.1002/hep.24692.

Meuleman P, et al. NIH Public Access. 2013;55(2):364–72. https://doi.org/10.1002/hep.24692.A.

Miller JP, Kigwana LJ, Streeter DG, Robins RK, Simon LN, Roboz J. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci. 1977;284(1):211–29. https://doi.org/10.1111/j.1749-6632.1977.tb21953.x.

Nasheri N, et al. Modulation of fatty acid synthase enzyme activity and expression during hepatitis C virus replication. Chem Biol. 2013;20(4):570–82. https://doi.org/10.1016/j.chembiol.2013.03.014.

Oh JY, et al. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. Korean J Int Med. 2019;34(4):794–801. https://doi.org/10.3904/kjim.2017.368.

Owens CM, et al. 1213 Cyclophilin inhibitor Edp-546 is a potential cornerstone drug for use in combination with Ns5a and protease inhibitors due to its high barrier to HCV resistance. J Hepatol. 2013;58:S493. https://doi.org/10.1016/s0168-8278(13)61214-3.

Patel MC, et al. Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014;9(9):811–29. https://doi.org/10.2217/fvl.14.70.

Pawlotsky JM, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. https://doi.org/10.1016/j.jhep.2018.03.026.

Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40. https://doi.org/10.3748/wjg.v22.i34.7824.

Raedler LA. Viekira pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets): all-oral fixed combination approved for genotype 1 chronic hepatitis C infection. Am Health Drug Benefits. 2015;8(Spec Feature):142–7.

Rajender Reddy K, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliv Rev. 2002;54:571–86.

Ramamurthy M, Sankar S, Kannangai R, Nandagopal B, Sridharan G. Application of viromics: a new approach to the understanding of viral infections in humans. VirusDis. 2017;28(4):349–59. https://doi.org/10.1007/s13337-017-0415-3.

Rigopoulou EI, Abbott WGH, Williams R, Naoumov NV. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res. 2007;75(1):36–42. https://doi.org/10.1016/j.antiviral.2006.11.008.

Saito H, Lund-Katz S, Phillips MC. Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog Lipid Res. 2004;43(4):350–80. https://doi.org/10.1016/j.plipres.2004.05.002.

Saraswat V, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries—volume 2. J Viral Hepat. 2015. https://doi.org/10.1111/jvh.12350.

Sarrazin C, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–6. https://doi.org/10.1016/j.antiviral.2015.01.003.

Schott E, et al. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. J Hepatol. 2007. https://doi.org/10.1016/j.jhep.2006.09.011.

Sezaki H, et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology. 2009;52(1):43–8. https://doi.org/10.1159/000213504.

da Silva Filho CE, Muench A. Soldering of a low gold content alloy (46%). Rev Odontol Univ Sao Paulo. 1989;3(4):481–4.

Summers WC. Virus infection. Encycl Microbiol. 2009;13(1):546–52. https://doi.org/10.1016/B978-012373944-5.00323-0.

Tanaka J, et al. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol. 2003;70(3):378–86. https://doi.org/10.1002/jmv.10406.

Tang H. Cyclophilin inhibitors as a novel HCV therapy. Viruses. 2010;2(8):1621–34. https://doi.org/10.3390/v2081621.

Uebelhoer L, et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 2008;4(9):1–15. https://doi.org/10.1371/journal.ppat.1000143.

Wang Y, et al. (-)-Epigallocatechin-3-gallate enhances hepatitis C virus double-stranded RNA intermediates-triggered innate immune responses in hepatocytes. Sci Rep. 2016;6:1–12. https://doi.org/10.1038/srep21595.

Yao H, Ye J. Long chain Acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells. J Biol Chem. 2008;283(2):849–54. https://doi.org/10.1074/jbc.M706160200.

Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa MR, AbuBakar S. “Novel antiviral activity of baicalein against dengue virus. BMC Complement Altern Med. 2012. https://doi.org/10.1186/1472-6882-12-214.

Zavaglia C, et al. Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. Liver Int. 2014. https://doi.org/10.1111/liv.12502.

Zeisel MB, Crouchet E, Baumert TF, Schuster C. Host-targeting agents to prevent and cure hepatitis C virus infection. Viruses. 2015;7(11):5659–85. https://doi.org/10.3390/v7112898.